These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 29427176)
21. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. Taylor PC; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Mack M; Kremer J J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463 [TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178 [TBL] [Abstract][Full Text] [Related]
23. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Combe B; Dasgupta B; Louw I; Pal S; Wollenhaupt J; Zerbini CA; Beaulieu AD; Schulze-Koops H; Durez P; Yao R; Vastesaeger N; Weng HH; Ann Rheum Dis; 2014 Aug; 73(8):1477-86. PubMed ID: 23740226 [TBL] [Abstract][Full Text] [Related]
25. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316 [TBL] [Abstract][Full Text] [Related]
26. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362 [TBL] [Abstract][Full Text] [Related]
28. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931 [TBL] [Abstract][Full Text] [Related]
29. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Ukyo Y; Ishii Y; Yoshinari T; Baker D; Mod Rheumatol; 2018 Sep; 28(5):770-779. PubMed ID: 29219638 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442 [TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. Navarro-Millán I; Herrinton LJ; Chen L; Harrold L; Liu L; Curtis JR PLoS One; 2016; 11(3):e0149781. PubMed ID: 27007811 [TBL] [Abstract][Full Text] [Related]
33. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME; Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393 [TBL] [Abstract][Full Text] [Related]
34. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. Schulze-Koops H; Giacomelli R; Samborski W; Rednic S; Herold M; Yao R; Govoni M; Vastesaeger N; Weng HH Clin Exp Rheumatol; 2015; 33(2):201-8. PubMed ID: 25664404 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial. Buttgereit F; Aelion J; Rojkovich B; Zubrzycka-Sienkiewicz A; Chen S; Yang Y; Arikan D; D'Cunha R; Pang Y; Kupper H; Radstake T; Amital H Arthritis Rheumatol; 2023 Jun; 75(6):879-889. PubMed ID: 36512671 [TBL] [Abstract][Full Text] [Related]
36. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702 [TBL] [Abstract][Full Text] [Related]
38. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306 [TBL] [Abstract][Full Text] [Related]
39. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539 [TBL] [Abstract][Full Text] [Related]
40. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Smolen JS; Kay J; Doyle M; Landewé R; Matteson EL; Gaylis N; Wollenhaupt J; Murphy FT; Xu S; Zhou Y; Hsia EC Arthritis Res Ther; 2015 Jan; 17(1):14. PubMed ID: 25627338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]